Edition:
United States

Celyad SA (CYAD.OQ)

CYAD.OQ on NASDAQ Stock Exchange Global Market

41.70USD
16 Feb 2018
Change (% chg)

$-0.37 (-0.88%)
Prev Close
$42.07
Open
$41.97
Day's High
$41.97
Day's Low
$41.70
Volume
35
Avg. Vol
1,573
52-wk High
$64.00
52-wk Low
$20.58

Chart for

About

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure,... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 17 2017

BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial ‍​

* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL ‍​

Oct 03 2017

BRIEF-Celyad SA files for mixed shelf offering of up to $250 mln

* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing ‍​ Source text: [http://bit.ly/2xBg9Sn] Further company coverage:

Aug 31 2017

BRIEF-Celyad H1 operating loss narrows to 13.7 million euros

* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO

Aug 29 2017

Earnings vs. Estimates